Apyx Medical Corporation (NASDAQ: APYX), the maker of the Renuvion® helium plasma and radiofrequency platform, has announced a peer-reviewed article in Plastic and Reconstructive Surgery—Global Open. The study compares Renuvion’s Helium Plasma Technology with InMode’s Bipolar RF System following liposuction or body contouring procedures.
This retrospective, single-center study, led by Michael Kluska, DO, analyzed data from over 450 patients treated with either Renuvion (n=229) or Bipolar RF (n=236). Both groups were similar in demographics, including age, sex, BMI, and tobacco use.
The study found that patients treated with Renuvion experienced significantly fewer adverse events (p-value <0.0001) compared to those treated with Bipolar RF. Specifically, 45 adverse events occurred in 34 patients using Renuvion, versus 93 events in 62 patients using Bipolar RF. Of these, 28 adverse events in the Renuvion group were deemed procedure-related, compared to 69 in the Bipolar RF group. Notably, the Renuvion group had fewer cases of burns, hematoma, hypertrophic scars, and seromas.
The researchers concluded that Renuvion may be a safer alternative to Bipolar RF for managing skin laxity after liposuction or body contouring. They emphasized that Renuvion offers superior safety, shorter procedure times, and higher patient satisfaction.
Charlie Goodwin, President and CEO of Apyx Medical, stated, “We are pleased with the publication of this study, which supports Renuvion’s enhanced safety outcomes compared to a commonly used technology. This study adds to the growing clinical evidence of Renuvion’s safety and efficacy, reinforcing our commitment to delivering innovative, evidence-based solutions in cosmetic surgery.”
